RE:RE:pharmaguy and other experts..Q for you.. FDA ADcom BD's
pg, re. MAPI i suspect that beyond AdCom the completion of this process for TST is pretty straightforward but very involved, etc. so good on them to use outsider expertise...like i imagine the CMC stuff went well and the plant audit was a success (mostly as failure in these areas woulda leaked and price woulda collapsed) because as you know (way more than me) the FDA has specific requirements that they well publicize (what is it 550 points of data or summin like that)..
..BTW would MAPI have advised TST on the compositoin of their AdCom team??? cause when i see Amgen, etc. send EVP's, etc. to lead teams (and by comparison i suspect at best Berendt would be a VP in a company like Amgen) and we get a VP i gotta say failure somewhere..
regards
ps you got any good biotech picks and is PLI overpriced or is their future that bright, I started looking at them at $1.80 or so but didn't pull the trigger and it ran away